Douglas Fambrough is CEO at Dicerna Pharmaceuticals Inc (DRNA). They have made 7 open-market trades across 1 company since 2014, most recently 2021-12-28.
CIK 0001259856
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
4 open-market purchases totalling $489K since 2014, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| DRNA | BUY | 2021-08-10 | 2021-08-10 | $22.10 | $111K | -7.2% | -1.4% | +0.1% |
| DRNA | BUY | 2020-09-01 | 2020-09-01 | $18.06 | $181K | -1.3% | +0.8% | +36.3% |
| DRNA | SELL | 2019-12-18 | 2019-12-19 | $25.85 | $2.0M | -15.4% | -22.8% | -48.4% |
| DRNA | SELL | 2019-12-17 | 2019-12-19 | $26.00 | $7.2M | -15.4% | -22.8% | -48.4% |
| DRNA | SELL | 2019-12-17 | 2019-12-19 | $26.16 | $1.5M | -15.4% | -22.8% | -48.4% |
| DRNA | BUY | 2016-11-14 | 2016-11-16 | $3.71 | $123K | -16.7% | -18.9% | -22.7% |
| DRNA | BUY | 2014-01-29 | 2014-02-20 | $15.00 | $75K | -38.1% | -2.1% | -2.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.